Recap: Nuvectis Pharma Q3 Earnings
Portfolio Pulse from Benzinga Insights
Nuvectis Pharma (NASDAQ:NVCT) reported Q3 earnings, missing estimated earnings by 8.82% with an EPS of $-0.37 versus an estimate of $-0.34. Revenue was down $0 from the same period last year. Last quarter, the company also missed on EPS by $0.09, which was followed by a 0.4% increase in the share price the next day.
November 08, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Nuvectis Pharma missed Q3 earnings estimates, reporting an EPS of $-0.37. Despite a similar miss last quarter, the share price increased by 0.4% the following day.
Nuvectis Pharma's Q3 earnings miss is a negative signal. However, the company's stock price increased after a similar miss last quarter, suggesting that investors may have already priced in the risk of earnings misses. Therefore, the short-term impact on the stock price is uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100